IE
PLX icon

Israel Englander’s Protalix BioTherapeutics PLX Stock Holding History

Israel Englander’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$400K Buy
+171,535
New +$363K ﹤0.01% 4936
2025
Q2 		– Sell
-963,011
Closed -$2.47M – 6229
2025
Q1 		$2.47M Buy
963,011
+575,090
+148% +$1.37M ﹤0.01% 3581
2024
Q4 		$729K Buy
387,921
+14,164
+4% +$20K ﹤0.01% 4453
2024
Q3 		$381K Sell
373,757
-437,403
-54% -$460K ﹤0.01% 5036
2024
Q2 		$949K Buy
811,160
+800,676
+7,637% +$946K ﹤0.01% 4144
2024
Q1 		$13.2K Buy
+10,484
New +$15.7K ﹤0.01% 5881
2023
Q3 		– Sell
-21,232
Closed -$42.5K – 6455
2023
Q2 		$42.5K Sell
21,232
-65,466
-76% -$156K ﹤0.01% 5505
2023
Q1 		$182K Buy
+86,698
New +$152K ﹤0.01% 5209
2022
Q3 		– Sell
-19,223
Closed -$21K – 7396
2022
Q2 		$21K Buy
+19,223
New +$22.5K ﹤0.01% 6474
2017
Q1 		– Sell
-11,010
Closed -$49K – 3768
2016
Q4 		$49K Buy
+11,010
New +$49.2K ﹤0.01% 3254
2013
Q4 		– Sell
-3,439
Closed -$156K – 3706
2013
Q3 		$156K Buy
3,439
+1,734
+102% +$89K ﹤0.01% 3147
2013
Q2 		$84K Buy
+1,705
New +$90.5K ﹤0.01% 2881

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Israel Englander's PLX Position: Q2 2026 in Review

Israel Englander opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 171,535 shares worth $400K. The stake represents ﹤0.01% of the portfolio and ranks #4936 among its holdings. This is a return to the name: Israel Englander previously reported a position in PLX as recently as Q1 2025.

Israel Englander first reported a position in PLX in Q2 2013 and has held it in 12 quarters since. The position peaked at $2.47M in Q1 2025. 101 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Israel Englander held 171,535 shares of Protalix BioTherapeutics worth $400K as of Q2 2026.
  • Protalix BioTherapeutics was a new Israel Englander position in Q2 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4936 holding.
  • Israel Englander first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 12 quarters since.
  • Israel Englander's Protalix BioTherapeutics position peaked at $2.47M in Q1 2025.
  • 101 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.